Skip to main content

Institute of Human Virology and Italian Researchers Find Higher Daily Temperatures Lead to a Decrease in COVID-19 Related Deaths

June 12, 2020 | Nora Samaranayake

(left to right) Francesca Benedetti, PhD, Davide Zella, PhD, and Robert Gallo, MD

Insights into population density and daily temperatures provide a path to public health strategies

The Institute of Human Virology (IHV) at the University of Maryland School of Medicine, a Global Virus Network (GVN) Center of Excellence, in collaboration with scientists from Campus Biomedico in Rome and Ulisse Biomed and University of Trieste, in Trieste, Italy announced today the results of studies showing an inverse correlation between average high daily temperatures and COVID-19 related death rates in different geographical areas.

By comparing data for the months of March and April 2020 in 25 regions in Europe and the U.S., the researchers observed that in March, when temperatures were uniform and lockdowns did not exist, there was no difference in the number of COVID-19 related deaths, while in April, when lockdown was implemented, there was a statistically significant correlation between average monthly high temperatures with reduced number of deaths per one million people. These data, which will be published by the Journal of Translational Medicine, suggest that social distancing measures are more successful in the presence of higher daily average temperatures in reducing the death rates of COVID-19.

“Correlating higher temperatures with COVID-19 related deaths is a step forward in better understanding how environmental factors can affect SARS-CoV-2,” said Davide Zella, PhD, Assistant Professor of Biochemistry and Molecular Biology at the Institute of Human Virology, University of Maryland School of Medicine. “Data like these, expanded and confirmed, could potentially help in determining the many variables needed to tailor lockdown measures to different geographical areas.”

“Our data provide more understanding regarding the impact of daily temperatures and COVID-19 related death rates, and serves as a model that can advise economists and public health officials to target future regions at higher risk of COVID-19 outbreaks,” said Francesca Benedetti, PhD, Research Associate of Biochemistry and Molecular Biology at the Institute of Human Virology, University of Maryland School of Medicine.

“This research is an extension of work done by IHV’s Mohammad Sajadi and Anthony Amoroso presented in March,” said Robert C. Gallo, MD, The Homer & Martha Gudelsky Distinguished Professor, Co-founder & Director at the Institute of Human Virology, University of Maryland School of Medicine and Co-Founder and Chairman of the International Scientific Leadership Board of the Global Virus Network (GVN).  “Scientists, including those within the Global Virus Network, will be able to expand upon these findings to help the private sector and government officials better prepare for future outbreaks, whether it’s SARS-CoV-2 or the next global threat.”

“We are pleased that our previous hypothesis linking cold weather and viral spread within the community has been confirmed by these new data,” said Mohammad Sajadi, MD, Associate Professor of Medicine at the Institute of Human Virology, University of Maryland School of Medicine. Dr. Sajadi, together with Anthony Amoroso, MD, Associate Professor of Medicine, and Chief of Clinical Care Programs, Institute of Human Virology, University of Maryland School of Medicine and Associate Chief of Infectious Diseases, University of Maryland School of Medicine, proposed the hypothesis that distribution of COVID-19 along restricted latitude, temperature, and humidity was consistent with the behavior of a seasonal respiratory virus.  Dr. Sajadi and Dr. Amoroso are developing a real-time forecasting model of climate conditions that are favorable to the spread of COVID-19.

About the Institute of Human Virology

Formed in 1996 as a partnership between the State of Maryland, the City of Baltimore, the University System of Maryland, and the University of Maryland Medical System, the IHV is an institute of the University of Maryland School of Medicine and is home to some of the most globally-recognized and world-renowned experts in all of virology. The IHV combines the disciplines of basic research, epidemiology, and clinical research in a concerted effort to speed the discovery of diagnostics and therapeutics for a wide variety of chronic and deadly viral and immune disorders - most notably, HIV the virus that causes AIDS. For more information, visit www.ihv.org and follow us on Twitter @IHVmaryland.

Contact

Institute of Human Virology
Nora Samaranayake
Director of Marketing and Public Relations
(410) 706-8614 (phone)
(410) 706-1952 (fax)
nsamaranayake@ihv.umaryland.edu

Related stories

    Friday, August 28, 2020

    WYPR: Could Polio Vaccine Corral Covid-19?

    A safe, effective vaccine against Covid-19 could resurrect jobs, send kids back to classrooms--change our lives. But how safe and effective? And how quickly can we have it? Dr. Robert Gallo, the AIDS-research pioneer now leading virus science at the Institute of Human Virology at the University of Maryland School of Medicine and the Global Virus Network, argues we could get much of the benefit by inoculating people with an old, very cheap drug -- the oral Polio vaccine developed seven decades ago. Gallo contends it would trigger our ‘innate immunity’-- the body’s emergency response when a threat shows up.


    Friday, August 21, 2020

    Institute of Human Virology and Italian Researchers identify a SARS-CoV-2 Viral Strain with Deletion in a Protein, Possibly Reducing Fatalities

    The Institute of Human Virology (IHV) at the University of Maryland School of Medicine, a Global Virus Network (GVN) Center of Excellence, in collaboration with scientists from Campus Biomedico in Rome, Italy announced today the results of studies showing the emergence of a SARS-CoV-2 viral strain with a deletion in a protein known as nsp1. These data, accepted for publication today by the Journal of Translational Medicine, (link here) may indicate the emergence of a less pathogenic viral strain.


    Monday, August 03, 2020

    Eureka, Charles River Laboratories: Could the Oral Polio Vaccine be Used to Prevent COVID-19?

    Virologist Robert Gallo, MD, has had a long and storied career in academic and government research. He is the Homer & Martha Gudelsky Distinguished Professor in Medicine, co-founder and director of the Institute Human Virology (IHV) at the University of Maryland School of Medicine and co-founder and international scientific adviser of the Global Virus Network. Despite his deep roots in HIV, Dr. Gallo’s current focus is, not surprisingly, COVID-19, which emerged in China last year and within four months morphed into a full-blown pandemic. As usual, Dr. Gallo’s research strategy has raised eyebrows. Unlike the antibody and RNA vaccines that are all the rage in COVID-19 science, Gallo is putting his energies behind repurposing the oral polio virus vaccine developed in the 1950s by Albert Sabin.


    Monday, August 03, 2020

    Infectious Disease Special Edition: COVID-19 and HIV: Was It a Deadly Mix?

    Social distancing is one of the curses of COVID-19, and may fall more heavily on people with HIV than on those without this burden. “People with HIV, and in particular certain subsets of that group—the LGBTQ community, older adults aging with HIV, etc.—face more mental health issues than the general population,” said Sarah Schmalzle, MD, an assistant professor of medicine at the Institute of Human Virology, University of Maryland School of Medicine, in Baltimore. “Many of our patients also already face significant isolation and loneliness due to a combination of HIV stigma, losses of friends and family to HIV, and aging.”


    Friday, July 31, 2020

    RollingStone-Useful Idiots: Dr. Robert Gallo on a COVID-19 Vaccine

    Dr. Robert Gallo, director of the Institute for Human Virology at the University of Maryland School of Medicine, joins the show to give his take on the prospects for an effective COVID-19 vaccine. Gallo is skeptical of the approach many organizations are taking with antibody vaccines, citing the similarly low efficacy those treatments had with HIV due to the low durability of the antibodies. Dr. Gallo’s research is mainly related to Oral Polio Vaccine, which he thinks needs to be tested more in regard to innate immunity.


    Monday, July 20, 2020

    NPR: Early Oxford-AstraZeneca Coronavirus Vaccine Data 'Encouraging,' Scientists Say

    Dr. Robert Gallo is quoted about an experimental vaccine candidate being developed by AstraZeneca and Oxford University to protect against COVID-19 that triggered an immune response against the coronavirus and appeared to be safe.


    Tuesday, July 07, 2020

    Courthouse News Service: Global Progress on Ending HIV/AIDS Derailed by Covid-19

    A United Nations program aimed at eliminating HIV/AIDS released a report Monday showing that the global response to the epidemic has fallen far short of goals set for 2020, in large part due to the coronavirus pandemic.


    Monday, July 06, 2020

    Sputnik Radio: What If There Is No Vaccine for COVID-19?

    On today's episode of Loud & Clear, Brian Becker and John Kiriakou are joined by Robert Gallo, MD, the Homer & Martha Gudelsky Distinguished Professor in Medicine, co-founder and director of the Institute Human Virology at the University of Maryland School of Medicine and co-founder and international scientific adviser of the Global Virus Network. What would you think if someone told you that we already have a vaccine that at least helps fight Covid-19? That may already be the case. Two American scientists, Dr. Robert Gallo and Dr. Konstantin Chumakov, are positing that decades-old live vaccines for things like polio and tuberculosis strengthen the immune system’s first line of defense a more general way to fight infection. And the history books show us that that sometimes translates into at least some cross-protection against completely different viruses.


    Friday, July 03, 2020

    KUSI San Diego News: Dr. Robert Gallo suggests an oral polio vaccine could help fight coronavirus

    Dr. Robert Gallo from the Institute of Human Virology at the University of Maryland School of Medicine and Global Virus Network wrote an op-ed in the Wall Street Journal earlier this week. The opinion piece stated that OPV, oral polio vaccine, could be a cheap and effective way to fight coronavirus. Dr. Gallo discussed his opinion piece on Good Morning San Diego.


    Thursday, July 02, 2020

    13D Global Strategy & Research Report

    COVID-19 outbreaks are multiplying and immunity may be short-lived. Could existing “live” vaccines, which stimulate innate immunity, outshine vaccines targeting the “spike” protein?


    Tuesday, June 30, 2020

    Wall Street Journal Op-Ed: An Old Vaccine May Help Against Coronavirus: A tablet for polio boosts innate immunity, which fights other viruses.

    In this op-ed coauthored by Dr. Robert C. Gallo and Daniel J. Arbess, they discuss how “An Old Vaccine May Help Against Coronavirus: A tablet for polio boosts innate immunity, which fights other viruses.”


    Monday, June 29, 2020

    Baltimore Magazine Special Edition: Dr. Gallo Featured

    Dr. Robert Gallo is featured in Baltimore Magazine's special edition, "On the Front Lines: Acts of Courage and Kindness in the Age of Coronavirus."


    Friday, June 26, 2020

    IHV in the News

    Links to news stories featuring the IHV from June 11 to June 25, 2020.


    Thursday, June 25, 2020

    The New York Times: Dr. Robert Gallo: The Case for a Stopgap Vaccine

    In a letter to the editor to The New York Times entitled, "Dr. Robert Gallo: The Case for a Stopgap Vaccine," the noted virologist and head of the IHV says a polio vaccine may be an ideal solution until we find a Covid-specific vaccine.


    Wednesday, June 24, 2020

    The New York Times: Decades-Old Soviet Studies Hint at Coronavirus Strategy

    The New York Times: Decades-Old Soviet Studies Hint at Coronavirus Strategy: A married pair of virologists in Moscow tested a vaccine on their own children in the 1950s. Now, a side effect they found is sparking new hope for a defense against the coronavirus.


    Tuesday, June 23, 2020

    France 24: Dr. Mohammad Sajadi Speaks with France 24 on COVID-19 and Seasonality

    Does Covid-19 spread faster in winter? Modelling by US researchers suggests the transmission of Covid-19 could be seasonal. Mohammad Sajadi, associate professor at University of Maryland School of Medicine's Institute of Human Virology, says the virus first spread in areas of low temperature and low humidity, common to winter time in temperate areas.


    Friday, June 12, 2020

    The Washington Post: We shouldn’t care who wins the vaccine ‘race’

    Dr. Robert Gallo writes a Letter to the Editor to The Washington Post entitled, “We shouldn’t care who wins the vaccine ‘race’,” regarding their June 4 front-page article “Cold War echoes in race for vaccine,” about the “race” among nations, notably the United States, China, and Russia and other European nations for development of a vaccine against the novel coronavirus.


    Friday, June 12, 2020

    CNN Health: An Existing Polio Vaccine Could Help Protect Against Coronavirus, Top Experts Say

    CNN: There is plenty of evidence that existing inoculations such as polio vaccines protect children against a wide range of infections and it's worth trying them out against the new coronavirus, a team of experts wrote in Science magazine Thursday.


    Thursday, June 11, 2020

    NBC News: Polio Vaccine Could Give Temporary Protection Against COVID-19, Scientists Hope

    NBC News: As the world waits for a coronavirus vaccine, some scientists are proposing that existing vaccines could give the body’s immune system a much-needed temporary boost to stave off infection. It’s still unclear whether such an approach would work, and some experts are skeptical. Others — including researchers in Israel, the Netherlands and Australia — are already investigating whether a tuberculosis vaccine could help jump-start the immune system and make COVID-19 less deadly, though the World Health Organization strongly advises against using that vaccine until it’s proven effective against the coronavirus.


    Thursday, June 11, 2020

    Global Virus Network Suggests Oral Polio Vaccine May Provide Temporary Protection Against COVID-19

    The Global Virus Network (GVN), a coalition comprised of the world’s preeminent human and animal virologists from 53 Centers of Excellence, including the Institute of Human Virology at the University of Maryland School of Medicine, and 10 Affiliates in 32 countries, published a viewpoint in Science today that the stimulation of innate immunity by live attenuated vaccines in general, and oral poliovirus vaccine (OPV) in particular, could provide temporary protection against coronavirus disease 2019 (COVID-19).


    Tuesday, June 02, 2020

    UM School of Medicine’s Institute of Human Virology Awarded Grants to Strengthen COVID-19 Response in Sub-Saharan Africa

    The Center for International Health, Education and Biosecurity (Ciheb) at the University of Maryland School of Medicine’s Institute of Human Virology was awarded $4 million from the U.S. Centers for Disease Control and Prevention (CDC) to support coronavirus disease 2019 (COVID-19) response activities in Botswana, Nigeria, Malawi, and Mozambique.


    Monday, May 11, 2020

    BBC Global News Interviews Dr. Robert Gallo on Oral Polio Vaccine for SARS-CoV-2 and More

    Dr. Robert Gallo appeared on BBC World News with Matthew Amroliwala for a one-on-one, lengthy interview during their Coronavirus Explained segment.


    Thursday, March 19, 2020

    What COVID-19 Symptoms Look Like, Day By Day

    (Source: Business Insider) According to the World Health Organization-China Joint Mission on COVID-19, as of February 20, 80% of laboratory-confirmed cases were mild to moderate, 14% were severe, and 6% were critical. Just to be clear, a mild case of COVID-19 is not like a mild cold. The symptoms will still be pretty severe. Anything less than needing oxygen puts you in this category. Severe cases do need supplemental oxygen, and critical ones are defined by respiratory or multi-organ failure.